Table 2.
Baseline demographic and clinical characteristics
| NeP populationa: baseline painb | ||||
|---|---|---|---|---|
| Moderate | Severe | |||
| Pregabalin | Placebo | Pregabalin | Placebo | |
| N | 333 | 180 | 150 | 79 |
| Age, years, median (range) | 66 (24–92) | 65 (28–88) | 69 (27–88) | 68 (27–87) |
| Sex, n (%) | ||||
| Female | 118 (35.4) | 52 (28.9) | 66 (44.0) | 22 (27.9) |
| Male | 215 (64.6) | 128 (71.1) | 84 (56.0) | 57 (72.2) |
| Duration of NeP-related pain, months, mean (SD) | 44.2 (50.4) | 47.2 (45.9) | 53.3 (65.9) | 49.7 (49.3) |
| Pain score,b mean (SD) | 5.4 (0.8) | 5.4 (0.8) | 8.0 (0.9) | 7.9 (0.8) |
| Sleep score,c mean (SD) | 3.2 (2.1) | 3.5 (2.0) | 5.3 (2.8) | 5.4 (2.8) |
Notes: Subjects with baseline pain <4 and missing baseline pain scores are excluded.
a
Includes pregabalin 150, 300, 600 mg/day, and flexible 150–600 mg/day treatment groups.
b
Pain scores range from 0=no pain to 10=worst possible pain; scores of ≥4–<7 were classified as moderate and ≥7–≤10 were classified as severe.
c
Sleep scores range from 0=pain does not interfere with sleep to 10=pain completely interferes with sleep.
Abbreviation: NeP, neuropathic pain.